drugset / Trial / NCT00615186
Glioblastoma Multiforme (GBM) Locoregional Agent Survival Study - Anti-tenascin Radiolabeled Antibody Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The current study will investigate whether the addition of Neuradiab to surgery, radiation and adjuvant chemotherapy (temozolomide) will improve the survival of patients with glioblastoma and whether the drug regimen is safe.
Timeline
- Start
- 2008-06
- Primary completion
- 2013-08
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Neuradiab | Monoclonal antibody | — | — |
| Comparator | Temozolomide | Small molecule | 150 mg/m2 | — |
| Comparator | Temozolomide | Small molecule | 200 mg/m2 | — |